Safe Care CommitmentGet the care you need even during COVID-19.Learn more
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation (View details on clinicaltrial.gov)
A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (View details on clinicaltrial.gov)
A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (View details on clinicaltrial.gov)
A Phase 1 Study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML) (View details on clinicaltrial.gov)
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (View details on clinicaltrial.gov)
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers (View details on clinicaltrial.gov)
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (View details on clinicaltrial.gov)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) (View details on clinicaltrial.gov)
A Phase 1b/2a open-label, multi-center study to assess the safety, efficacy and pharmacokinetics of intrapatient dose-adjusted brequinar and inhibition of dihydroorotate dehydrogenase (DHODH) in adult subjects with acute myelogenous leukemia (AML) (View details on clinicaltrial.gov)
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis (View details on clinicaltrial.gov)